


# BIOSIMILARS: A Safe & Effective Option for Patients

In the U.S., biosimilar usage and approvals are on the rise; access to these safe, effective treatments offer patients improved health outcomes. For more information, visit [www.biosimilarscouncil.org](http://www.biosimilarscouncil.org).



A biosimilar is a biologic medicine that is

**highly similar**  
to a brand biologic medicine.

**7** Approved



FDA has approved 7 biosimilars<sup>1</sup> to treat patients suffering from RA, Crohn's Disease, cancer, psoriasis and other conditions;

**60+**  
more in development<sup>2,3</sup>


**~35** Available



In Europe, ~35 biosimilars available in at least 8 therapeutic classes<sup>4</sup>



Same safety and efficacy as their biologic counterpart



Same mechanism of action



Rigorous FDA testing and review; Less cost to patients and the health system



Companies that manufacture biosimilars are committed to providing safe, effective products

Biosimilars are  
**safe, effective, more affordable and offer improved patient access.**



**safe**



**effective**



**affordable**



**access**

Visit us:

<http://biosimilarscouncil.org/>



[/Biosimscouncil](https://www.facebook.com/Biosimscouncil)



[@biosimscouncil](https://twitter.com/biosimscouncil)

#### References

1. Statement of Chester "Chip" Davis, Jr., Senate Health, Education, Labor and Pensions Committee. Available at <http://bit.ly/2yAanD7>. Accessed October 19, 2017.
2. Biosimilars Implementation: Testimony of Janet Woodcock, M.D. to the U.S. House of Representatives February 4, 2016. Available at: <http://bit.ly/2nmE2bc>. Accessed March 13, 2017.
3. Biosimilars to Drive Modern Manufacturing Approaches. Available at: <http://bit.ly/2nmE2bc>. Accessed March 13, 2017.
4. Biosimilars Approved in Europe. Available at: <http://bit.ly/2vY8hvt>. Accessed August 23, 2017.